CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD19 positive
|
NHL
|
CD19 positive
|
NHL
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks (NewA1)
|
blinatumomab Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks - (New A1)
|
CD19 positive
|
ALL
|
CD19 positive
|
ALL
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CTX110 Sensitive: B - Late Trials
|
CTX110 Sensitive: B - Late Trials
|
CD19 positive
|
NHL
|
CD19 positive
|
NHL
|
CTX110 Sensitive: B - Late Trials
|
CTX110 Sensitive: B - Late Trials
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CAR-T immunotherapy Sensitive: C3 – Early Trials
|
CAR-T immunotherapy Sensitive: C3 – Early Trials
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
YT-19 Sensitive: C3 – Early Trials
|
YT-19 Sensitive: C3 – Early Trials
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
PBCAR0191 Sensitive: C3 – Early Trials
|
PBCAR0191 Sensitive: C3 – Early Trials
|
CD19 positive
|
Small Lymphocytic Lymphoma
|
CD19 positive
|
Small Lymphocytic Lymphoma
|
T-lymphocyte cell therapy Sensitive: C4 – Case Studies
|
T-lymphocyte cell therapy Sensitive: C4 – Case Studies
|
CD19 positive
|
CLL
|
CD19 positive
|
CLL
|
T-lymphocyte cell therapy Sensitive: C4 – Case Studies
|
T-lymphocyte cell therapy Sensitive: C4 – Case Studies
|
CD19 positive
|
ALL
|
CD19 positive
|
ALL
|
FT596 Sensitive: D – Preclinical
|
FT596 Sensitive: D – Preclinical
|
CD19 positive
|
NHL
|
CD19 positive
|
NHL
|
ISIKOK-19 Sensitive: D – Preclinical
|
ISIKOK-19 Sensitive: D – Preclinical
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
ISIKOK-19 Sensitive: D – Preclinical
|
ISIKOK-19 Sensitive: D – Preclinical
|